Adagio Medical Holdings, INC Form 4 insider transactions

Sean Salmon, a Director of Adagio Medical Holdings, Inc., received 30,000 shares of common stock on June 16, 2026.

Keyvan Mirsaeedi-Farahani, a Director of Adagio Medical Holdings, Inc., received 30,000 shares of common stock on June 16, 2026.

James L Cox, a Director of Adagio Medical Holdings, Inc., received 30,000 shares of common stock on June 16, 2026.

Sandra A. Gardiner, a Director of Adagio Medical Holdings, Inc., received 30,000 shares of common stock on June 16, 2026.

Orly Mishan, a Director of Adagio Medical Holdings, Inc., received 100,000 shares of common stock on June 16, 2026.

Timothy P. Moran, a Director of Adagio Medical Holdings, Inc., received 30,000 shares of common stock on June 16, 2026.

Adagio Medical Holdings, Inc.'s Chief Financial Officer, Deborah Kaster, reported an open market purchase of 15,000 shares of common stock.

Adagio Medical Holdings, Inc. CEO Todd Usen acquired 207,315 shares of common stock in an open market purchase, signaling confidence in the company.

Adagio Medical Holdings, Inc. Director Sean Salmon was granted 90,000 non-qualified stock options with an exercise price of $0.8779, vesting over 36 months.

Perceptive Advisors and affiliates reported the acquisition of common and pre-funded warrants in Adagio Medical Holdings, Inc. through a public offering.

Director James L. Cox acquires non-qualified stock options in Adagio Medical Holdings, Inc. under the company's 2024 Equity Incentive Plan.

Sandra A. Gardiner, a director of Adagio Medical Holdings, Inc., reported the acquisition of non-qualified stock options for 90,000 shares on March 20, 2025.

Keyvan Mirsaeedi-Farahani, a director at Adagio Medical Holdings, acquired 90,000 non-qualified stock options on March 20, 2025, according to a Form 4 filing.

Director Orly Mishan of Adagio Medical Holdings acquires 300,000 non-qualified stock options under the company's 2024 Equity Incentive Plan.

Director Timothy P. Moran reports acquisition of 90,000 non-qualified stock options in Adagio Medical Holdings, Inc.

Perceptive Advisors and related entities acquire shares of Adagio Medical Holdings in exchange for waiving rights related to the company's debt default.

Adagio Medical Holdings CEO, Todd Usen, reports the acquisition of employee stock options.

ARYA Sciences Holdings IV executed a pro rata distribution of Adagio Medical Holdings common stock to its shareholders on September 27, 2024.

Olav Bergheim, CEO of Adagio Medical Holdings, reports acquisition of shares through Fjordinvest LLC and Micro NV LLC following a business combination.

Hakon Bergheim, Chief Operating Officer of Adagio Medical Holdings, reports the acquisition of common stock and stock options as a result of the business combination with ARYA Sciences Acquisition Corp IV.

Director James L. Cox reports acquisition of 36,698 shares of Adagio Medical Holdings, Inc. common stock following a business combination.

ARYA Sciences Acquisition Corp IV announces shareholder approval of the business combination with Adagio Medical, paving the way for the deal's expected completion on July 29, 2024.

ARYA Sciences Acquisition Corp IV announces Sandra Gardiner as an additional director nominee for New Adagio and provides updates on PIPE financing, including a potential increase in investment from Perceptive Life Sciences Master Fund.

ARYA Sciences Acquisition Corp IV obtains a $150,000 convertible promissory note from its sponsor to fund working capital and extend the period for completing a business combination.

ARYA Sciences Acquisition Corp IV has amended its business combination agreement with Adagio Medical and secured additional PIPE financing to support the merger.

ARYA Sciences Acquisition Corp IV provides an updated investor presentation regarding its business combination with Adagio Medical, Inc.

ARYA Sciences Acquisition Corp IV extends its business combination deadline to July 2, 2024, and draws additional funds from its sponsor to facilitate the extension and for general working capital.

Adagio Medical announces the first European commercial procedures using its VT Cryoablation System and FDA approval for its FULCRUM-VT Pivotal IDE study.

ARYA Sciences Acquisition Corp IV extends its business combination deadline to June 2, 2024, and draws $185,000 from a convertible promissory note for the extension and general working capital.

Adagio Medical gains FDA approval to increase study sites and subjects for its pivotal cryoablation study, marking a significant step towards potential market approval.